Chronic hepatitis C: treatments of the future (Q39661182)

13 September 2017

Chronic hepatitis C: treatments of the future (English)

1 reference

13 September 2017

1 reference

1 reference

1 reference

Marc Bourlière

1

1 reference

13 September 2017

Asma Khaloun

2

1 reference

13 September 2017

Claire Wartelle-Bladou

3

1 reference

13 September 2017

Valérie Oules

4

1 reference

13 September 2017

Isabelle Portal

5

1 reference

13 September 2017

Souad Benali

6

1 reference

13 September 2017

Xavier Adhoute

7

1 reference

13 September 2017

Paul Castellani

8

1 reference

13 September 2017

1 December 2011

1 reference

Clinics and research in hepatology and gastroenterology

13 September 2017

1 reference

13 September 2017

35 Suppl 2

1 reference

13 September 2017

S84-95

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

13 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Second-wave protease inhibitors: choosing an heir

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

New protease inhibitors for HCV--help is on the way.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

The HCV NS5B nucleoside and non-nucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

The NS5A replication complex inhibitors: difference makers?

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Hepatitis C therapy: other players in the game

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970013-4

7 January 2021

10.1016/S2210-7401(11)70013-4

Identifiers

DOI

1 reference

13 September 2017

1 reference